DFS in Stage II/IIIA

ADAURA investigated oral, adjuvant TAGRISSO over a planned treatment duration of 3 years

Adjuvant TAGRISSO reduced the risk of disease recurrence or death by an overwhelming 83% in the primary endpoint subset (Stage II/IIIA)1,2

DFS in Stage II/IIIA DFS in Stage II/IIIA
Back to Top Back to Top


A key secondary endpoint

Adjuvant TAGRISSO demonstrated consistently impressive DFS benefit across Stage IB, II, and IIIA resected EGFRm NSCLC1,2

Back to Top Back to Top

Rates of recurrence

According to an exploratory analysis

In the ADAURA study, adjuvant TAGRISSO significantly protected against the risk of distant disease recurrences, including in the central nervous system (CNS)1*

Rates of recurrence Rates of recurrence
Adjuvant TAGRISSO achieved an 82% reduction in the risk of recurrence to the CNS (HR=0.18 [95% CI: 0.10, 0.33])
Back to Top Back to Top

Subgroup analyses

In resected EGFRm NSCLC

Adjuvant TAGRISSO delivered clear DFS benefit across patient subgroups1

Subgroup analyses Subgroup analyses
Adjuvant TAGRISSO demonstrated consistent DFS benefit regardless of stage, race, smoking history, or use of prior adjuvant chemotherapy
Back to Top Back to Top

Study design

ADAURA was a global Phase III study designed to investigate adjuvant TAGRISSO in patients with resected (Stage IB, II, or IIIA) EGFRm NSCLC1

Study designStudy design

Primary endpoint: Disease-free survival (DFS) in patients with Stage II to IIIA NSCLC1

Secondary endpoints: DFS in overall population, DFS at 2, 3, and 5 years, overall survival, safety, health-related quality of life1,3

  • The ADAURA study was powered to show a hazard ratio (HR) of 0.7 in favour of the TAGRISSO arm1
Although interim results were independently unblinded due to overwhelming efficacy, patients and investigators remain blinded to treatment1

References: 1. Wu Y-L, Tsuboi M, He J, et al; ADAURA Investigators. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020. doi:10.1056/NEJMoa2027071. 2. AstraZeneca Pharmaceuticals. TAGRISSO® (osimertinib). Summary of Product Characteristics, 2021. 3. AstraZeneca. AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA). Available from: https://www.clinicaltrials.gov/ct2/show/NCT02511106. NLM identifier: NCT02511106. Accessed March 8, 2021.